Drug Trial Radar · NCT01527305
A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
Last checked: Nov 20, 2026Latest source record: Oct 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
212
Actual
Start
Jun 22, 2012
Primary completion
Dec 31, 2013
Study completion Dec 31, 2013
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Feb 7, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness and safety of paliperidone palmitate in schizophrenic inpatients who have experienced recent exacerbation of acute schizophrenia (that is within past 4 weeks).
Conditions
- Schizophrenia
Interventions
Paliperidone palmitateDrug
Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total ScoreTime frame: Baseline (Week 0), Week 13
Locations
21 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Huzhou, China
Site not named
Shanghai, China
Site not named
Shantou, China
Site not named
Suzhou, China
Site not named
Wenzhou, China
Site not named
Wuxi, China
Site not named
Johor Bahru, Malaysia
Site not named
Kuala Lumpur, Malaysia
Site not named
Tanjong Rambutan, Malaysia
Site not named
Busan, South Korea
Site not named
Goyang, South Korea
Site not named
Gyeonggi-do, South Korea
Site not named
Jeonju, South Korea
Site not named
Kyounggi, South Korea
Site not named
Seoul, South Korea
Site not named
Suwon, South Korea
Site not named
Douliou City, Yunlin County, Taiwan
Site not named
Kaohsiung City, Taiwan
Site not named
New Taipei City, Taiwan
Site not named
Taichung, Taiwan
Site not named
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.